Chronic obstructive pulmonary disease: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
(removing duplicate reference definitions)
 
(41 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{subpages}}
{{subpages}}
{{TOC|right}}
{{TOC|right}}
'''Chronic obstructive pulmonary disease''' ('''COPD'''), also known as '''chronic obstructive airway disease''' ('''COAD'''), is an [[obstructive lung disease]] that is characterized by the pathological limitation of airflow in the [[airway]] that is ''not'' fully reversible. This contrasts to [[asthma]] which is a [[obstructive lung disease]] in which the obstructive is reversible.
'''Chronic obstructive pulmonary disease''' ('''COPD'''), also known as '''chronic obstructive airway disease''' ('''COAD'''), is an [[obstructive lung disease]] that is characterized by the pathological limitation of airflow in the [[airway]] that is ''not'' fully reversible. This contrasts to [[asthma]], an [[obstructive lung disease]] in which the obstruction is reversible.


COPD is the umbrella term for [[chronic bronchitis]], [[emphysema]] and a range of other lung disorders. It is most often due to [[tobacco smoking]],<ref name="dev">Devereux G. ''ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors.'' [[British Medical Journal|BMJ]] 2006;332:1142-1144. PMID 16690673</ref> but can be due to other airborne irritants such as [[coal dust]], [[asbestos]] or [[solvents]], as well as [[congenital]] conditions such as [[alpha-1-antitrypsin deficiency]].
COPD is the umbrella term for [[chronic bronchitis]], [[emphysema]] and a range of other lung disorders. It is most often due to [[tobacco smoking]],<ref name="dev">Devereux G. ''ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors.'' [[British Medical Journal|BMJ]] 2006;332:1142-1144. PMID 16690673</ref> but can be due to other airborne irritants such as [[coal dust]], [[asbestos]] or [[solvents]], as well as [[congenital]] conditions such as [[alpha-1-antitrypsin deficiency]].


== Signs and symptoms ==
== Signs and symptoms ==
The main [[symptoms]] of COPD include [[dyspnea]] (shortness of breath) lasting for months or perhaps years, possibly accompanied by [[wheezing]], and a persistent [[cough]] with [[sputum]] production.<ref>[http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_SignsAndSymptoms.html U.S. National Heart Lung and Blood Institute - Signs and Symptoms]</ref> It is possible the sputum may contain blood ([[hemoptysis]]), usually due to damage of the blood vessels of the airways. Severe COPD could lead to [[cyanosis]] (bluish decolorization usually in the lips and fingers) caused by a lack of [[oxygen]] in the blood. In extreme cases it could lead to [[cor pulmonale]] due to the extra work required by the heart to get blood to flow through the lungs.<ref>[http://www.medicinenet.com/chronic_obstructive_pulmonary_disease_copd/page4.htm MedicineNet.com - COPD signs & symptoms]</ref>
The main [[symptoms]] of COPD include [[dyspnea]] (shortness of breath) lasting for months or perhaps years, possibly accompanied by [[wheezing]], and a persistent [[cough]] with [[sputum]] production.<ref>[http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_SignsAndSymptoms.html U.S. National Heart Lung and Blood Institute - Signs and Symptoms]</ref> It is possible the sputum may contain blood ([[hemoptysis]]), usually due to damage of the blood vessels of the airways. Severe COPD could lead to [[cyanosis]] (bluish decolorization usually in the lips and fingers) caused by a lack of [[oxygen]] in the blood. In extreme cases it could lead to [[cor pulmonale]] due to the extra work required by the heart to get blood to flow through the lungs.<ref>[http://www.medicinenet.com/chronic_obstructive_pulmonary_disease_copd/page4.htm MedicineNet.com - COPD signs & symptoms]</ref>  


COPD is particularly characterised by the [[Spirometry|spirometric measurement]] of a ratio of forced expiratory volume over 1 second ([[FEV1|FEV<sub>1</sub>]]) to forced vital capacity (FVC) being < 0.7 and the [[FEV1|FEV<sub>1</sub>]]  < 70% of the predicted value <ref>[http://www.patient.co.uk/showdoc/40002357/ PatientPlus - Spirometry]</ref> as measured by a [[plethysmograph]]. Other [[signs]] include a rapid breathing rate ([[tachypnea]]) and a wheezing sound heard through a [[stethoscope]]. Pulmonary emphysema is NOT the same as subcutaneous emphysema, which is a collection of air under the skin that may be detected by the [[crepitus|crepitus sounds]] produced on [[palpation]].<ref>[http://www.emedicine.com/med/topic209.htm eMedicine - Barotrauma]</ref>
COPD is particularly characterised by the [[Spirometry|spirometric measurement]] of a ratio of forced expiratory volume over 1 second ([[FEV1|FEV<sub>1</sub>]]) to forced vital capacity (FVC) being < 0.7 and the [[FEV1|FEV<sub>1</sub>]]  < 70% of the predicted value <ref>[http://www.patient.co.uk/showdoc/40002357/ PatientPlus - Spirometry]</ref> as measured by a [[plethysmograph]]. Other [[signs]] include a rapid breathing rate ([[tachypnea]]) and a wheezing sound heard through a [[stethoscope]]. Pulmonary emphysema is NOT the same as subcutaneous emphysema, which is a collection of air under the skin that may be detected by the [[crepitus|crepitus sounds]] produced on [[palpation]].<ref>[http://www.emedicine.com/med/topic209.htm eMedicine - Barotrauma]</ref>
Line 12: Line 12:
==Causes==
==Causes==
===Cigarette smoking===
===Cigarette smoking===
A primary risk factor of COPD is chronic tobacco smoking. In the [[United States]], around 90% of cases of COPD are due to smoking.<ref name="medcauses">[http://www.medicinenet.com/chronic_obstructive_pulmonary_disease_copd/page3.htm7whatcauses MedicineNet.com - COPD causes]</ref> Not all smokers will develop COPD, but continuous smokers have at least a 25% risk.<ref>Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. ''Thorax''. 2006 Nov;61(11):935-9. PMID 17071833</ref>
A primary risk factor of COPD is chronic tobacco smoking. In the [[United States of America]], around 90% of cases of COPD are due to smoking.<ref name="medcauses">[http://www.medicinenet.com/chronic_obstructive_pulmonary_disease_copd/page3.htm7whatcauses MedicineNet.com - COPD causes]</ref> Not all smokers will develop COPD, but continuous smokers have at least a 25% risk.<ref>Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. ''Thorax''. 2006 Nov;61(11):935-9. PMID 17071833</ref>


===Occupational pollutants===
===Occupational pollutants===
Line 39: Line 39:


== Diagnosis ==
== Diagnosis ==
[[Clinical practice guideline]]s by a collaboration of American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society address diagnosis.<ref name="pmid21810710">{{cite journal| author=Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T et al.| title=Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. | journal=Ann Intern Med | year= 2011 | volume= 155 | issue= 3 | pages= 179-91 | pmid=21810710 | doi=10.1059/0003-4819-155-3-201108020-00008 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21810710  }} </ref>
The diagnosis of COPD is suggested by symptoms; it is a clinical diagnosis and no single test is definitive. A history is taken of smoking and occupation, and a physical examination is done. Measurement of lung function with a [[spirograph]] can reveal the loss of lung function.  
The diagnosis of COPD is suggested by symptoms; it is a clinical diagnosis and no single test is definitive. A history is taken of smoking and occupation, and a physical examination is done. Measurement of lung function with a [[spirograph]] can reveal the loss of lung function.  


Line 64: Line 66:


== Management ==
== Management ==
Although COPD is not curable, it can be controlled in a variety of ways.  [[Clinical practice guideline]]s by [http://www.goldcopd.org/ Global Initiative for Chronic Obstructive Lung Disease] (GOLD)<ref name="pmid17507545">{{cite journal |author=Rabe KF, Hurd S, Anzueto A, ''et al'' |title=Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary |journal=Am. J. Respir. Crit. Care Med. |volume=176 |issue=6 |pages=532-55 |year=2007 |pmid=17507545 |doi=10.1164/rccm.200703-456SO}}</ref>, a collaboration including the American [http://www.nhlbi.nih.gov National Heart, Lung, and Blood Institute] and the [http://www.who.org World Health Organization], as well as [[Clinical practice guideline|guidelines]] by the [[American College of Physicians]]<ref name="pmid17975186">{{cite journal |author=Qaseem A, Snow V, Shekelle P, ''et al'' |title=Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians |journal=Ann. Intern. Med. |volume=147 |issue=9 |pages=633–8 |year=2007 |pmid=17975186 |doi=|url=http://annals.org/cgi/content/full/147/9/633}}</ref><ref name="pmid17975187">{{cite journal |author=Wilt TJ, Niewoehner D, MacDonald R, Kane RL |title=Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline |journal=Ann. Intern. Med. |volume=147 |issue=9 |pages=639–53 |year=2007 |pmid=17975187 |doi=|url=http://annals.org/cgi/content/full/147/9/639}}</ref> are available.
Although COPD is not curable, it can be controlled in a variety of ways.  [[Clinical practice guideline]]s by [http://www.goldcopd.org/ Global Initiative for Chronic Obstructive Lung Disease] (GOLD)<ref name="pmid17507545"/>, a collaboration including the American [http://www.nhlbi.nih.gov National Heart, Lung, and Blood Institute] and the [http://www.who.org World Health Organization], as well as [[Clinical practice guideline|guidelines]] by the [[American College of Physicians]] published in 2011<ref>{{Cite journal
| doi = 10.1059/0003-4819-155-3-201108020-00008
| volume = 155
| issue = 3
| pages = 179 -191
| last = Qaseem
| first = Amir
| coauthors = Timothy J. Wilt, Steven E. Weinberger, Nicola A. Hanania, Gerard Criner, Thys van der Molen, Darcy D. Marciniuk, Tom Denberg, Holger Schünemann, Wisia Wedzicha, Roderick MacDonald, Paul Shekelle
| title = Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society
| journal = Annals of Internal Medicine
| accessdate = 2011-08-03
| date = 2011
| url = http://www.annals.org/content/155/3/179.abstract
}}</ref> and 2007<ref name="pmid17975186">{{cite journal |author=Qaseem A, Snow V, Shekelle P, ''et al'' |title=Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians |journal=Ann. Intern. Med. |volume=147 |issue=9 |pages=633–8 |year=2007 |pmid=17975186 |doi=|url=http://annals.org/cgi/content/full/147/9/633}}</ref><ref name="pmid17975187">{{cite journal |author=Wilt TJ, Niewoehner D, MacDonald R, Kane RL |title=Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline |journal=Ann. Intern. Med. |volume=147 |issue=9 |pages=639–53 |year=2007 |pmid=17975187 |doi=|url=http://annals.org/cgi/content/full/147/9/639}}</ref> are available.


===Smoking cessation===
===Smoking cessation===
Line 75: Line 90:
===Pharmacotherapy===
===Pharmacotherapy===
====Bronchodilators====
====Bronchodilators====
There are several types of [[bronchodilators]] used clinically with varying efficacy: β<sub>2</sub> agonists, M<sub>3</sub> antimuscarinics, leukotriene antagonists, cromones and xanthines.<ref name=thoracic>American Thoracic Society / European Respiratory Society Task Force (2005). ''Standards for the Diagnosis and Management of Patients with COPD''. Version 1.2. New York: American Thoracic Society. http://www.thoracic.org/go/copd</ref> These drugs relax the [[smooth muscles]] of the airway allowing for improved airflow. The change in [[FEV1|FEV<sub>1</sub>]] may not be substantial, but changes in the [[vital capacity]] are significant. Many patients feel less breathless after taking bronchodilators.
There are several types of [[bronchodilators]] used clinically with varying efficacy: β<sub>2</sub> agonists, M<sub>3</sub> antimuscarinics, leukotriene antagonists, cromones and xanthines.<ref name=thoracic>American Thoracic Society / European Respiratory Society Task Force (2005). ''Standards for the Diagnosis and Management of Patients with COPD''. Version 1.2. New York: American Thoracic Society. http://www.thoracic.org/go/copd</ref> These drugs relax the [[smooth muscles]] of the airway allowing for improved airflow. Patients may feel less breathless after taking bronchodilators.
 
Older studies showed:
* The β<sub>2</sub> agonists and M<sub>3</sub> antimuscarinics probably have similar efficacy<ref name="pmid16856113">{{cite journal |author=Appleton S, Jones T, Poole P, ''et al.'' |title=Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease |journal=Cochrane Database Syst Rev |volume=3 |issue= |pages=CD006101 |year=2006 |pmid=16856113 |doi=10.1002/14651858.CD006101 |url=http://dx.doi.org/10.1002/14651858.CD006101 |issn=}}</ref>
* All cause mortality may be worse for antimuscarinic according to a nested [[case-control study]].<ref name="pmid18794557">{{cite journal |author=Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB |title=Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease |journal=Ann. Intern. Med. |volume=149 |issue=6 |pages=380–90 |year=2008 |month=September |pmid=18794557 |doi= |url= |issn=}}</ref>
 
More recent studies conclude differently and are in the table.


{| class="wikitable"
{| class="wikitable"
|+ Major [[meta-analysis|meta-analyses]] and [[randomized controlled trial]]s of<br/>bronchodilators for reducing all-cause mortality from COPD.<ref name="pmid18460518">{{cite journal |author=Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R |title=Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review |journal=Chest |volume=133 |issue=5 |pages=1079–87 |year=2008 |month=May |pmid=18460518 |doi=10.1378/chest.07-1167 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18460518 |issn=}}</ref><ref name="pmid18812535">{{cite journal |author=Singh S, Loke YK, Furberg CD |title=Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis |journal=JAMA |volume=300 |issue=12 |pages=1439–50 |year=2008 |month=September |pmid=18812535 |doi=10.1001/jama.300.12.1439 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=18812535 |issn=}}</ref>
|+ Major [[meta-analysis|meta-analyses]] and [[randomized controlled trial]]s of<br/>bronchodilators for reducing all-cause mortality from COPD.<ref name="pmid18836213">{{cite journal |author=Tashkin DP, Celli B, Senn S, ''et al.'' |title=A 4-year trial of tiotropium in chronic obstructive pulmonary disease |journal=N. Engl. J. Med. |volume=359 |issue=15 |pages=1543–54 |year=2008 |month=October |pmid=18836213 |doi=10.1056/NEJMoa0805800 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18836213&promo=ONFLNS19 |issn=}}</ref><ref name="pmid18812535">{{cite journal |author=Singh S, Loke YK, Furberg CD |title=Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis |journal=JAMA |volume=300 |issue=12 |pages=1439–50 |year=2008 |month=September |pmid=18812535 |doi=10.1001/jama.300.12.1439 |url=http://jama.ama-assn.org/cgi/content/full/300/12/1439 |issn=}}</ref><ref name="pmid18460518">{{cite journal |author=Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R |title=Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review |journal=Chest |volume=133 |issue=5 |pages=1079–87 |year=2008 |month=May |pmid=18460518 |doi=10.1378/chest.07-1167 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18460518 |issn=}}</ref><ref name="pmid17314337">{{cite journal |author=Calverley PM, Anderson JA, Celli B, ''et al'' |title=Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease |journal=N. Engl. J. Med. |volume=356 |issue=8 |pages=775–89 |year=2007 |month=February |pmid=17314337 |doi=10.1056/NEJMoa063070 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17314337&promo=ONFLNS19 |issn=}}</ref>
! rowspan="2"|Study/design!!rowspan="2"|Patients!!rowspan="2"|Intervention!!rowspan="2"|Outcome!!colspan="2"|Results!!rowspan="2"|Comments
! rowspan="2"|Study/design!!rowspan="2"|Patients!!rowspan="2"|Intervention!!rowspan="2"|Outcome!!colspan="2"|Results!!rowspan="2"|Comments
|-
|-
! Treatment group!!Control group
! Treatment group!!Control group
|-
| Uplift study.<ref name="pmid18836213"/><br/>[[Randomized controlled trial]], 2008||5993 patients|| [[Tiotropium]] || All-cause mortality at 4 years||align="center"|14.9% †||align="center"|16.5%||The Uplift study was too recent to be in the Singh meta-analysis.<br/>"tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV<sub>1</sub>"
|-
|-
| Singh et al.<ref name="pmid18812535"/><br/>[[Meta-analysis]], 2008||14,783 in 17 trials|| Inhaled anticholinergics|| All-cause mortality||align="center"|2%||align="center"|1.6%||"Inhaled anticholinergics are associated with a significantly increased risk of cardiovascular death, MI, or stroke among patients with COPD"
| Singh et al.<ref name="pmid18812535"/><br/>[[Meta-analysis]], 2008||14,783 in 17 trials|| Inhaled anticholinergics|| All-cause mortality||align="center"|2%||align="center"|1.6%||"Inhaled anticholinergics are associated with a significantly increased risk of cardiovascular death, MI, or stroke among patients with COPD"
Line 87: Line 110:
| Rodrigo et al.<ref name="pmid18460518"/><br/>[[Meta-analysis]], 2008|| 20,527 in 27 trials||Long-Acting β-Agonists|| All-cause mortality||align="center"| 4.9%||align="center"|6.5%||"did not confirm previous data about an increased risk for respiratory deaths"
| Rodrigo et al.<ref name="pmid18460518"/><br/>[[Meta-analysis]], 2008|| 20,527 in 27 trials||Long-Acting β-Agonists|| All-cause mortality||align="center"| 4.9%||align="center"|6.5%||"did not confirm previous data about an increased risk for respiratory deaths"
|-
|-
| rowspan="3"|TORCH Study.<ref name="pmid18460518"/><br/>Factorial [[randomized controlled trial]], 2007||rowspan="3"|6112 patients||Long-Acting β-Agonists combined with inhaled corticosteroids||rowspan="3"|All-cause mortality at 3 years||align="center"|12.6%||align="center"|15.2%||rowspan="3"|This is the major trial in the Rodrigo meta-analysis
| rowspan="3"|TORCH Study.<ref name="pmid17314337"/><br/>Factorial [[randomized controlled trial]], 2007||rowspan="3"|6112 patients||Long-Acting β-Agonists combined with inhaled corticosteroids||rowspan="3"|All-cause mortality at 3 years||align="center"|12.6%||align="center"|15.2%||rowspan="3"|This is the major trial in the Rodrigo meta-analysis
|-
|-
| Long-Acting β-Agonists||align="center"|13.5%||align="center"|15.2%
| Long-Acting β-Agonists||align="center"|13.5%||align="center"|15.2%
Line 98: Line 121:
=====β<sub>2</sub> agonists=====
=====β<sub>2</sub> agonists=====
{{main|Adrenergic beta-agonist}}
{{main|Adrenergic beta-agonist}}
There is a tendency for long acting β<sub>2</sub> agonists to reduce death, especially if they are combined with an inhaled corticosteroid.<ref name="pmid17943918">{{cite journal |author=Nannini LJ, Cates CJ, Lasserson TJ, Poole P |title=Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease |journal=Cochrane Database Syst Rev |volume= |issue=4 |pages=CD006829 |year=2007 |pmid=17943918 |doi=10.1002/14651858.CD006829 |url=http://dx.doi.org/10.1002/14651858.CD006829 |issn=}}</ref><ref name="pmid18460518">{{cite journal |author=Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R |title=Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review |journal=Chest |volume=133 |issue=5 |pages=1079–87 |year=2008 |month=May |pmid=18460518 |doi=10.1378/chest.07-1167 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18460518 |issn=}}</ref><ref name="pmid17314337">{{cite journal |author=Calverley PM, Anderson JA, Celli B, ''et al'' |title=Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease |journal=N. Engl. J. Med. |volume=356 |issue=8 |pages=775–89 |year=2007 |month=February |pmid=17314337 |doi=10.1056/NEJMoa063070 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17314337&promo=ONFLNS19 |issn=}}</ref> β<sub>2</sub> agonists may slow progression of airway obstruction<ref name="pmid18511702">{{cite journal |author=Celli BR, Thomas NE, Anderson JA, ''et al'' |title=Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study |journal=Am. J. Respir. Crit. Care Med. |volume=178 |issue=4 |pages=332–8 |year=2008 |month=August |pmid=18511702 |doi=10.1164/rccm.200712-1869OC |url=http://ajrccm.atsjournals.org/cgi/pmidlookup?view=long&pmid=18511702 |issn=}}</ref>.
There is a tendency for long acting β<sub>2</sub> agonists to reduce death, especially if they are combined with an inhaled corticosteroid.<ref name="pmid17943918">{{cite journal |author=Nannini LJ, Cates CJ, Lasserson TJ, Poole P |title=Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease |journal=Cochrane Database Syst Rev |volume= |issue=4 |pages=CD006829 |year=2007 |pmid=17943918 |doi=10.1002/14651858.CD006829 |url=http://dx.doi.org/10.1002/14651858.CD006829 |issn=}}</ref><ref name="pmid18460518">{{cite journal |author=Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R |title=Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review |journal=Chest |volume=133 |issue=5 |pages=1079–87 |year=2008 |month=May |pmid=18460518 |doi=10.1378/chest.07-1167 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=18460518 |issn=}}</ref><ref name="pmid17314337"/> β<sub>2</sub> agonists may slow progression of airway obstruction<ref name="pmid18511702">{{cite journal |author=Celli BR, Thomas NE, Anderson JA, ''et al'' |title=Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study |journal=Am. J. Respir. Crit. Care Med. |volume=178 |issue=4 |pages=332–8 |year=2008 |month=August |pmid=18511702 |doi=10.1164/rccm.200712-1869OC |url=http://ajrccm.atsjournals.org/cgi/pmidlookup?view=long&pmid=18511702 |issn=}}</ref>.


An increased risk is associated with long acting β<sub>2</sub> agonists among patients with ''asthma'' due to decreased sensitivity to inflammation so generally the use of a concomitant [[corticosteroid]] is indicated <ref>[http://www.fda.gov/medwatch/SAFETY/2003/serevent.htm]</ref><ref>[http://www.gsk.com/press_archive/press2003/press_01232003.htm]</ref>.
An increased risk is associated with long acting β<sub>2</sub> agonists among patients with ''asthma'' due to decreased sensitivity to inflammation so generally the use of a concomitant [[corticosteroid]] is indicated <ref>[http://www.fda.gov/medwatch/SAFETY/2003/serevent.htm]</ref><ref>[http://www.gsk.com/press_archive/press2003/press_01232003.htm]</ref>.
Line 104: Line 127:
There are several highly specific β<sub>2</sub> agonists available. [[Salbutamol]] (Ventolin) is the most widely used short acting β<sub>2</sub> agonist to  provide rapid relief and should be prescribed as a front line therapy for all classes of patients. Other β<sub>2</sub> agonists are [[Bambuterol]], [[Clenbuterol]], Fenoterol, and [[Formoterol]]. Longer acting β<sub>2</sub> agonists such as [[Salmeterol]] act too slowly to be used as relief for [[dypsnea]] so these drugs should be used as a secondary therapy.
There are several highly specific β<sub>2</sub> agonists available. [[Salbutamol]] (Ventolin) is the most widely used short acting β<sub>2</sub> agonist to  provide rapid relief and should be prescribed as a front line therapy for all classes of patients. Other β<sub>2</sub> agonists are [[Bambuterol]], [[Clenbuterol]], Fenoterol, and [[Formoterol]]. Longer acting β<sub>2</sub> agonists such as [[Salmeterol]] act too slowly to be used as relief for [[dypsnea]] so these drugs should be used as a secondary therapy.


=====M<sub>3</sub> muscarinic antagonists (anticholinergics)=====
=====M<sub>3</sub> muscarinic cholinergic antagonists=====
Derived from the deadly agaric ''[[Amanita muscaria]]'', specific [[antimuscarinics]] were found to provide effective relief to COPD. Inhaled antimuscarinics have the advantage of avoiding [[endocrine]] and [[exocrine]] M<sub>3</sub> receptors. The quaternary M<sub>3</sub> muscarinic antagonist [[Ipratropium]] is widely prescribed with the β<sub>2</sub> agonist [[salbutamol]].
Antagonists of the [[acetylcholine receptor]] include inhaled antimuscarinics. Antimuscarinics specific for M<sub>3</sub> muscarinic recetpro the have the advantage of avoiding [[endocrine]] and [[exocrine]] M<sub>1</sub> receptors. The quaternary M<sub>3</sub> muscarinic antagonist [[Ipratropium]] can be prescribed alone or is offered combined with salbutamol (Combivent) and with fenoterol (Duovent). [[Tiotropium]] provides improved specificity for M<sub>3</sub> muscarinic receptors and has been beneficial in trials.<ref name="pmid16144890">{{cite journal |author=Niewoehner DE, Rice K, Cote C, ''et al.'' |title=Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial |journal=Ann. Intern. Med. |volume=143 |issue=5 |pages=317–26 |year=2005 |month=September |pmid=16144890 |doi= |url=http://www.annals.org/cgi/content/full/143/5/317 |issn=}}</ref>
[http://www.neurosci.pharm.utoledo.edu/MBC3320/muscarinic.htm]. Ipratropium is offered combined with salbutamol (Combivent) and with fenoterol (Duovent). [[Tiotropium]] provides improved specificity for M<sub>3</sub> muscarinic receptors and has been beneficial in trials.<ref name="pmid16144890">{{cite journal |author=Niewoehner DE, Rice K, Cote C, ''et al.'' |title=Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial |journal=Ann. Intern. Med. |volume=143 |issue=5 |pages=317–26 |year=2005 |month=September |pmid=16144890 |doi= |url=http://www.annals.org/cgi/content/full/143/5/317 |issn=}}</ref>


Anticholinergics may increase adverse effects.<ref name="pmid18794557">{{cite journal |author=Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB |title=Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease |journal=Ann. Intern. Med. |volume=149 |issue=6 |pages=380–90 |year=2008 |month=September |pmid=18794557 |doi= |url=http://www.annals.org/cgi/content/full/149/6/380 |issn=}}</ref><ref>Sonal Singh, Yoon K. Loke, and Curt D. Furberg (2008). [http://jama.ama-assn.org/cgi/content/full/300/12/1439 Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis]. JAMA: The Journal of the American Medical Association 300 (12), 1439-50 (24 Sep 2008) {{doi|10.1001/jama.300.12.1439}}</ref>
Anticholinergics may increase adverse effects.<ref name="pmid18794557"/><ref name="pmid18812535"/>


=====Cromones=====
=====Cromones=====
Line 114: Line 136:


=====Leukotriene antagonists=====
=====Leukotriene antagonists=====
More recently [[leukotriene]] antagonists block the signaling molecules used by the immune system. [[Montelukast]], [[Pranlukast]], [[Zafirlukast]] are some of the leukotrienes antagonists.<ref name="pmid13804592">{{cite journal |author=BROCKLEHURST WE |title=The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock |journal=J. Physiol. (Lond.) |volume=151 |issue= |pages=416–35 |year=1960 |pmid=13804592 |doi=}}</ref>
More recently [[leukotriene antagonist]]s block the signaling molecules used by the immune system.<ref name="pmid21542741">{{cite journal| author=Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF et al.| title=Leukotriene antagonists as first-line or add-on asthma-controller therapy. | journal=N Engl J Med | year= 2011 | volume= 364 | issue= 18 | pages= 1695-707 | pmid=21542741 | doi=10.1056/NEJMoa1010846 | pmc= | url= }} </ref> [[Montelukast]], [[Pranlukast]], [[Zafirlukast]] are some of the leukotrienes antagonists.<ref name="pmid13804592">{{cite journal |author=BROCKLEHURST WE |title=The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock |journal=J. Physiol. (Lond.) |volume=151 |issue= |pages=416–35 |year=1960 |pmid=13804592 |doi=}}</ref>


=====Xanthines=====
=====Methylxanthines=====
[[Theophylline]] is the prototype of the [[xanthine]]<ref>http://www.chemistry.org/portal/a/c/s/1/acsdisplay.html?DOC=HomeMolecule\archive\motw_xanthine_arch.html</ref> class of drug. Teas are natural sources of methylxanthines, xanthines and [[caffeine]] while [[chocolate]] is a source of [[theobromine]]. [[Caffeine]] is approximately 16% metabolized into theophylline.
[[Theophylline]] is the prototype of the [[methylxanthine]]<ref>http://www.chemistry.org/portal/a/c/s/1/acsdisplay.html?DOC=HomeMolecule\archive\motw_xanthine_arch.html</ref> class of drug. Teas are natural sources of [[theophylline]] and [[caffeine]] while [[chocolate]] is a source of [[theobromine]]. [[Caffeine]] is approximately 16% metabolized into theophylline. Relatively little used, aminophylline as a derivative of theophylline, which can be given intraveously (IV).


Nebulized theophylline has uncertain value when used in the EMR for treatment of [[dyspnea]] (Difficulty in breathing).<ref name="pmid15939732">{{cite journal |author=Duffy N, Walker P, Diamantea F, Calverley PM, Davies L |title=Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial |journal=Thorax |volume=60 |issue=9 |pages=713–7 |year=2005 |month=September |pmid=15939732 |pmc=1747521 |doi=10.1136/thx.2004.036046 |url=http://thorax.bmj.com/cgi/pmidlookup?view=long&pmid=15939732 |issn=}}</ref> Patients need continual monitoring as theophylline has a narrow [[therapeutic range]]. More aggressive EMR interventions include IV H<sub>1</sub> [[antihistamine]]s and IV [[dexamethasone]].
Nebulized theophylline has uncertain value when used in the EMR for treatment of [[dyspnea]] (Difficulty in breathing).<ref name="pmid15939732">{{cite journal |author=Duffy N, Walker P, Diamantea F, Calverley PM, Davies L |title=Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial |journal=Thorax |volume=60 |issue=9 |pages=713–7 |year=2005 |month=September |pmid=15939732 |pmc=1747521 |doi=10.1136/thx.2004.036046 |url=http://thorax.bmj.com/cgi/pmidlookup?view=long&pmid=15939732 |issn=}}</ref> Patients need continual monitoring as theophylline has a narrow [[therapeutic range]]. More aggressive EMR interventions include IV H<sub>1</sub> [[antihistamine]]s and IV [[glucocorticoid]]s.


====Corticosteroids====
====Corticosteroids====
Inhaled [[corticosteriods]] (specifically [[glucocorticoids]]) act in the inflammatory cascade and may improve airway function considerably,<ref name=kc /> however the long term value has not been proven. Corticosteroids are often combined with bronchodilators in a single inhaler. Some of the more common inhaled steroids in use are [[beclomethasone]], [[Mometasone furoate|mometasone]], and [[fluticasone]].
<!--Inhaled [[corticosteroid]]s (specifically [[glucocorticoids]]) act in the inflammatory cascade and may improve airway function considerably,<ref name=kc /> however the long term value has not been proven. Corticosteroids are often combined with bronchodilators in a single inhaler. Some of the more common inhaled steroids in use are [[beclomethasone]], [[Mometasone furoate|mometasone]], and [[fluticasone]].-->
 
Although inhaled [[corticosteroid]]s can reduced the [[forced expiratory volume]] when added to long acting [[adrenergic beta-agonist]]s, they have uncertain benefit on clinical outcomes and may increase [[pneumonia]]<ref name="pmid19633090">{{cite journal| author=Rodrigo GJ, Castro-Rodriguez JA, Plaza V| title=Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. | journal=Chest | year= 2009 | volume= 136 | issue= 4 | pages= 1029-38 | pmid=19633090
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19633090 | doi=10.1378/chest.09-0821 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> [[Budesonide]] may not increase the risk of [[pneumonia]] due to quicker clearing from the airways according to a separate [[meta-analysis]].<ref name="pmid19716963">{{cite journal| author=Sin DD, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A et al.| title=Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. | journal=Lancet | year= 2009 | volume= 374 | issue= 9691 | pages= 712-9 | pmid=19716963
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19716963 | doi=10.1016/S0140-6736(09)61250-2 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
 
A factorial [[randomized controlled trial]] in the preceding meta-analyses compared [[salmeterol]] and [[fluticasone]] alone and in combination and found that the combination group tended to have the least mortality but that "the reduction in death from all causes among patients with COPD in the combination therapy group did not reach the predetermined level of statistical significance".<ref name="pmid17314337"/>
 
Inhaled [[fluticasone]] may increase the risk of pneumonia.<ref name="pmid17314337">{{cite journal |author=Calverley PM, Anderson JA, Celli B, ''et al'' |title=Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease |journal=N. Engl. J. Med. |volume=356 |issue=8 |pages=775–89 |year=2007 |month=February |pmid=17314337 |doi=10.1056/NEJMoa063070 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17314337&promo=ONFLNS19 |issn=}}</ref> [[Budesonide]] may not share this risk due to quicker clearing from the airways according to a [[meta-analysis]].<ref name="pmid19716963">{{cite journal| author=Sin DD, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A et al.| title=Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. | journal=Lancet | year= 2009 | volume= 374 | issue= 9691 | pages= 712-9 | pmid=19716963
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19716963 | doi=10.1016/S0140-6736(09)61250-2 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
 
Corticosteroids may be combined with bronchodilators in a single inhaler. Some of the more common inhaled steroids in use are [[beclomethasone]], [[Mometasone furoate|mometasone]], and [[fluticasone]].
 
Oral or intravenous [[corticosteriods]] can help treat exacerbations of COPD.<ref name="pmid17646228">{{cite journal |author=de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW |title=Oral or IV Prednisolone in the Treatment of COPD Exacerbations: A Randomized, Controlled, Double-blind Study |journal=Chest |volume=132 |issue=6 |pages=1741–7 |year=2007 |pmid=17646228 |doi=10.1378/chest.07-0208 |issn=}}</ref><ref name="pmid20551406">{{cite journal| author=Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB| title=Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. | journal=JAMA | year= 2010 | volume= 303 | issue= 23 | pages= 2359-67 | pmid=20551406
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20551406 | doi=10.1001/jama.2010.796 }} </ref>


Salmeterol and fluticasone are combined (Advair), however "the reduction in death from all causes among patients with COPD in the combination therapy group did not reach the predetermined level of statistical significance".<ref name="pmid17314337">{{cite journal |author=Calverley PM, Anderson JA, Celli B, ''et al'' |title=Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease |journal=N. Engl. J. Med. |volume=356 |issue=8 |pages=775–89 |year=2007 |pmid=17314337 |doi=10.1056/NEJMoa063070}} [http://clinicaltrials.gov/show/NCT00268216 Trial registration]</ref>
====Antiboitics====
[[Antibiotic]]s for acute exacerbations of COPD accelerate improvement of symptoms.<ref name="pmid19875685">{{cite journal| author=Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG| title=Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. | journal=Am J Respir Crit Care Med | year= 2010 | volume= 181 | issue= 2 | pages= 150-7 | pmid=19875685
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=19875685 | doi=10.1164/rccm.200906-0837OC }}
</ref>


Inhaled fluticasone may increase the risk of pneumonia.<ref name="pmid17314337">{{cite journal |author=Calverley PM, Anderson JA, Celli B, ''et al'' |title=Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease |journal=N. Engl. J. Med. |volume=356 |issue=8 |pages=775–89 |year=2007 |month=February |pmid=17314337 |doi=10.1056/NEJMoa063070 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17314337&promo=ONFLNS19 |issn=}}</ref>
Antibiotics may prevent exacerbations.
{| class="wikitable"
|+ [[Randomized controlled trial]]s af antibiotics to prevent exacerbations of COPD.<ref name="pmid21864166">{{cite journal| author=Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ et al.| title=Azithromycin for prevention of exacerbations of COPD. | journal=N Engl J Med | year= 2011 | volume= 365 | issue= 8 | pages= 689-98 | pmid=21864166 | doi=10.1056/NEJMoa1104623 | pmc= | url= }} </ref><ref name="pmid18723437">{{cite journal| author=Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA| title=Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. | journal=Am J Respir Crit Care Med | year= 2008 | volume= 178 | issue= 11 | pages= 1139-47 | pmid=18723437 | doi=10.1164/rccm.200801-145OC | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18723437  }} </ref>
! rowspan="2"|Trial!!rowspan="2"| Patients!!rowspan="2"| Intervention!!rowspan="2"|Comparison !!rowspan="2"|Outcome!!colspan="2"|Results!!rowspan="2"|Comment
|-<br/>
! Intervention!!Control
|-
| COPD Clinical Research Network<ref name="pmid21864166"/><br/>2011|| 1577 patients<br/>&bull;&nbsp;22% current smokers || azithromycin orally 250 mg daily||Placebo|| Mean number of exacerbations at 12 months|| 1.48|| 1.83||p = 0.01
|-
| Seemungal<ref name="pmid18723437"/><br/>2008 || 109 patients<br/>&bull;&nbsp;48% current smokers|| erythromycin orally 250 mg twice daily||Placebo|| Median number of exacerbations at 12 months|| 1|| 2||p = 0.006
|}


Oral or intravenous [[corticosteriods]] can help treat exacerbations of COPD.<ref name="pmid17646228">{{cite journal |author=de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW |title=Oral or IV Prednisolone in the Treatment of COPD Exacerbations: A Randomized, Controlled, Double-blind Study |journal=Chest |volume=132 |issue=6 |pages=1741–7 |year=2007 |pmid=17646228 |doi=10.1378/chest.07-0208 |issn=}}</ref>
====Mucolytic agents====
[[Mucolytic agent]]s such as [[N-acetylcysteine]] (NAC) 400 mg daily up to 600 mg daily, especially patients not already using inhaled [[corticosteroid]]s.<ref name="pmid20166060">{{cite journal| author=Poole P, Black PN| title=Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. | journal=Cochrane Database Syst Rev | year= 2010 | volume= 2 | issue= | pages= CD001287 | pmid=20166060
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20166060 | doi=10.1002/14651858.CD001287.pub3 }} </ref>


====TNF antagonists====
====TNF antagonists====
Tumor necrosis factor antagonists (TNF) are the most recent class of medications designed to deal with refractory cases. [[Tumor necrosis factor-alpha]] is a cachexin or cachectin and is considered a so-called biological drug. They are considerered immunosopressive with attendant risks. These rather expensive drugs include [[infliximab]], [[adalimumab]] and [[etanercept]].<ref>http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/C/CellSignaling.html</ref>
[[Tumor necrosis factor-alpha]] antagonists (TNF-a) are the most recent class of medications designed to deal with refractory cases. TNF-a is a cachexin or cachectin. Its inhibitors, all [[monoclonal antibody|monoclonal antibodies]]; they are immunosuppressive with attendant risks. These rather expensive drugs include [[infliximab]], [[adalimumab]] and [[etanercept]].<ref>http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/C/CellSignaling.html</ref>
 
===Narcotics===
{{main|Palliative care#Dyspnea}}
[[Opioid analgesic|Narcotic]]s may relieve dyspnea according to a [[systematic review]]<ref name="pmid12403875">{{cite journal| author=Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE| title=A systematic review of the use of opioids in the management of dyspnoea. | journal=Thorax | year= 2002 | volume= 57 | issue= 11 | pages= 939-44 | pmid=12403875
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12403875 | pmc=PMC1746225 }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12725627 Review in: ACP J Club. 2003 May-Jun;138(3):72]  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12882197 Review in: Evid Based Nurs. 2003 Jul;6(3):84]</ref> and more recent narrative review<ref name="pmid19786716">{{cite journal| author=Rocker G, Horton R, Currow D, Goodridge D, Young J, Booth S| title=Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. | journal=Thorax | year= 2009 | volume= 64 | issue= 10 | pages= 910-5 | pmid=19786716
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19786716 | doi=10.1136/thx.2009.116699 }} </ref>.
 
===Direct respiratory support===
Appropriate oxygen therapy is different in acute and chronic COPD.  "Oxygen is widely used but poorly studied in [[emergency medicine]], with a limited evidence base for its use in specific conditions. There are safety concerns about the underuse of oxygen in patients with critical illness and its overuse in conditions such as .." COPD <ref name=Hale2008>{{citation
|journal = Emerg Med J
| year = 2008
| volume = 25
| pages = 773-776
| doi=10.1136/emj.2008.059287
| title = Audit of oxygen use in emergency ambulances and in a hospital emergency department
| author = Hale KE, Gavin C, O'Driscoll BR
| url = http://emj.bmj.com/content/25/11/773.full
}}</ref>


====Supplemental Oxygen====
====Supplemental Oxygen====
In general, long-term administration of oxygen is usually reserved for individuals with COPD who have arterial [[hypoxemia]] ([[PaO2]] less than 55 mm Hg), or a PaO2 between 55 and 60 mm Hg with evidence of [[pulmonary hypertension]], [[cor pulmonale]], or secondary [[erythrocytosi]]s (hematocrit >55%). In these patients, continuous home oxygen therapy (for >15 h/d) sufficient to correct hypoxemia has been shown to improve survival.<ref name="pmid6110912">{{cite journal |author= |title=Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party |journal=Lancet |volume=1 |issue=8222 |pages=681–6 |year=1981 |pmid=6110912 |doi=10.1016/S0140-6736(81)91970-X }}</ref>
Excessive oxygen can produce [[hypercapnia]] and hypercapnic [[acidosis]] in patients with acute exacerbations of COPD. In 2006, 30 patients with a history of previous hypercapnic acidosis with a Pao2 >10.0 kPa—indicating that oxygen may have worsened the hypercapnia— were given  “O2 Alert” cards and a 24% Venturi mask. so that field and emergency room personnel do not cause iatrogenic hypercapnia. <ref name=Gooptul2006>{{citation
| journal = Emerg Med J
| year = 2006
| volume = 23 | pages = 636-638 | doi=10.1136/emj.2005
|title =Oxygen alert cards and controlled oxygen: preventing emergency admissions at risk of hypercapnic acidosis receiving high inspired oxygen concentrations in ambulances and A&E departments
| author = Gooptul B ''et al.''
| url = http://emj.bmj.com/content/23/8/636.full
}}</ref> A larger recent prospective trial in prehospital care randomized patients to receive high-flow oxygen or titrated oxygen. <ref>{{citation
| doi=  10.1136/bmj.c5462 |date =  18 October 2010
| journal = BMJ 2010| voluem = 341 | pages =c5462
| title = Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial
| author = Austin MA ''et al.''
| url = http://www.bmj.com/content/341/bmj.c5462.full
}}</ref>
*Titrating the oxygen,  compared with high flow oxygen. lowered the risk of death for all patients by 58% for all patients (relative risk 0.42, 95% confidence interval 0.20 to 0.89; P=0.02). Overall mortality was 9% (21 deaths) in the high flow oxygen arm compared with 4% (7 deaths) in the titrated oxygen arm; mortality in the subgroup with confirmed COPD was 9% (11 deaths) in the high flow arm compared with 2% (2 deaths) in the titrated oxygen arm. and by 78% for the patients with confirmed chronic obstructive pulmonary disease (0.22, 0.05 to 0.91; P=0.04).
*The risk of death was significantly lower in the titrated oxygen arm compared with the high flow oxygen arm for all patients (high flow oxygen n=226; titrated oxygen n=179) and for the subgroup of patients with confirmed COPD (high flow n=117; titrated n=97).
*Patients with COPD who received titrated oxygen according to the protocol were significantly less likely to have respiratory acidosis (mean difference in pH 0.12 (SE 0.05); P=0.01; n=28) or hypercapnia (mean difference in arterial carbon dioxide pressure −33.6 (16.3) mm Hg; P=0.02; n=29) than were patients who received high flow oxygen.
 
Long-term administration of oxygen is usually reserved for individuals with COPD who have arterial [[hypoxemia]] ([[PaO2]] less than 55 mm Hg), or a PaO2 between 55 and 60 mm Hg with evidence of [[pulmonary hypertension]], [[cor pulmonale]], or secondary [[erythrocytosi]]s (hematocrit >55%). In these patients, continuous home oxygen therapy (for >15 h/d) sufficient to correct hypoxemia has been shown to improve survival.<ref name="pmid6110912">{{cite journal |author= |title=Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party |journal=Lancet |volume=1 |issue=8222 |pages=681–6 |year=1981 |pmid=6110912 |doi=10.1016/S0140-6736(81)91970-X }}</ref>
 
====Noninvasive positive pressure ventilation====
[[Artificial respiration|Noninvasive positive pressure ventilation]], without raising the oxygen level, (NPPV) may help severe episodes.<ref name="pmid12779296">{{cite journal| author=Keenan SP, Sinuff T, Cook DJ, Hill NS| title=Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature. | journal=Ann Intern Med | year= 2003 | volume= 138 | issue= 11 | pages= 861-70 | pmid=12779296
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=12779296 }} </ref><ref name="pmid7651472">{{cite journal| author=Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A et al.| title=Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. | journal=N Engl J Med | year= 1995 | volume= 333 | issue= 13 | pages= 817-22 | pmid=7651472
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=7651472 }} </ref>


====Vaccination====
===Vaccination===
Patients with COPD should be routinely [[vaccination|vaccinated]] against [[influenza]], [[pneumococcus]] and other diseases to prevent illness and the possibility of death.<ref name="thoracic" />
Patients with COPD should be routinely [[vaccination|vaccinated]] against [[influenza]], [[pneumococcus]] and other diseases to prevent illness and the possibility of death.<ref name="thoracic" />


====Pulmonary rehabilitation====
===Pulmonary rehabilitation===
Pulmonary rehabilitation is a program of disease management, counseling and exercise coordinated to benefit the individual.<ref>[http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_Treatments.html U.S. National Heart Lung and Blood Institute - Treatment]</ref> Pulmonary rehabilitation has been shown to relieve difficulties breathing and fatigue. It has also been shown to improve the sense of control a patient has over their disease as well as their emotions.<ref>Lacasse Y, Goldstein R, Lasserson T J, Martin, S. ''Pulmonary rehabilitation for chronic obstructive pulmonary disease''. Cochrane Database of Systematic Reviews. (4):CD003793, 2006. PMID 12137716</ref>
Pulmonary rehabilitation is a program of disease management, counseling and exercise coordinated to benefit the individual.<ref>[http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_Treatments.html U.S. National Heart Lung and Blood Institute - Treatment]</ref> Pulmonary rehabilitation has been shown to relieve difficulties breathing and fatigue. It has also been shown to improve the sense of control a patient has over their disease as well as their emotions.<ref name="pmid21975749">{{cite journal| author=Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J| title=Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. | journal=Cochrane Database Syst Rev | year= 2011 | volume=  | issue= 10 | pages= CD005305 | pmid=21975749 | doi=10.1002/14651858.CD005305.pub3 | pmc= | url= }} </ref>
 
[[Clinical practice guideline]]s address the use of pulmonary rehabilitation.<ref name="pmid21810710">{{cite journal| author=Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T et al.| title=Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. | journal=Ann Intern Med | year= 2011 | volume= 155 | issue= 3 | pages= 179-91 | pmid=21810710 | doi=10.1059/0003-4819-155-3-201108020-00008 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21810710  }} </ref>
 
===Self management===
Self management may help the patients who are successful in learning management.<ref name="pmid22395923">{{cite journal| author=Bucknall CE, Miller G, Lloyd SM, Cleland J, McCluskey S, Cotton M et al.| title=Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. | journal=BMJ | year= 2012 | volume= 344 | issue=  | pages= e1060 | pmid=22395923 | doi=10.1136/bmj.e1060 | pmc=PMC3295724 | url= }} </ref>


===Diet===
===Diet===
Line 147: Line 244:


==Prognosis==
==Prognosis==
A good prognosis of COPD relies on an early diagnosis and prompt treatment. Most patients will have improvement in lung function once treatment is started, however eventually signs and symptoms will worsen as COPD progresses. The median survival is about 10 years if two-thirds of expected lung function was lost by diagnosis.
{| class="wikitable" align="right"
===Bronchitis===
|+ ADO index<ref name="pmid19716962">{{cite journal| author=Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Antó JM, Agustí AG et al.| title=Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. | journal=Lancet | year= 2009 | volume= 374 | issue= 9691 | pages= 704-11 | pmid=19716962
Acute bronchitis usually resolves in 7-10 days with no underlying lung disease. Chronic bronchitis however is dependent on early recognition and smoking cessation which improves the outcome significantly.
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19716962 | doi=10.1016/S0140-6736(09)61301-5 }} </ref>
! &nbsp;!!0 points!! 1 points!! 2 points!! 3 points!! 4 points!! 5 points
|-
| FEV<sub>1</sub>|| ≥65%||36% - 64% || ≤ 35% || || ||
|-
| Dyspnea ([[Medical Research Council dyspnea scale|MRC dyspnea scale]])|| 0 - 1||2 || 3 ||4 || ||
|-
| Age (years)|| 40 - 49||50 - 59 || 60 - 69 ||70 - 79 ||80 - 89 || ≥ 90
|-
| colspan="7"|From Table 6<ref name="pmid19716962"/>
|}


===Emphysema===
{| class="wikitable" align="center"
The outcome is better for patients with less damage to the lung who stop smoking immediately. Still, patients with extensive lung damage may live for many years so predicting prognosis is difficult. Death may occur from respiratory failure, [[pneumonia]], or other complications.
|+ ADO (age, dyspnea, obstruction) index and 3 year mortality<ref name="pmid19716962">{{cite journal| author=Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Antó JM, Agustí AG et al.| title=Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. | journal=Lancet | year= 2009 | volume= 374 | issue= 9691 | pages= 704-11 | pmid=19716962
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19716962 | doi=10.1016/S0140-6736(09)61301-5 }} </ref>
! &nbsp;!!0 points!! 1 points!! 2 points!! 3 points!! 4 points!! 5 points!! 6 points!! 7 points!! 8 points!! 9 points!! 10 points
|-
| Patients with longstanding and severe COPD||7%||10% || 14% ||18% ||24%||31%||39%||47%||56%||64%||72%
|-
| Patients after first hospitalization|| 3%||4%|| 5% ||7% ||10% ||13%||17%||22%||28%||34%||42%
|-
| colspan="12"|From Table 7<ref name="pmid19716962"/>
|}


===Asbestosis ===
Various [[clinical prediction rule]]s are available to estimate prognosis.<ref name="pmid19716962">{{cite journal| author=Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Antó JM, Agustí AG et al.| title=Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. | journal=Lancet | year= 2009 | volume= 374 | issue= 9691 | pages= 704-11 | pmid=19716962
The outcome is clouded by the many complications associated with asbestosis. [[Malignant]] [[mesothelioma]] is refractory to management affording patients with 6-12 months of life expectancy upon clinical presentation.
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19716962 | doi=10.1016/S0140-6736(09)61301-5 }} </ref>


===Pneumoconiosis===
The outcome is good for patients with minimal damage to the lung. However, patients with extensive lung damage may live for many years so predicting prognosis is difficult. Death may occur from [[respiratory failure]], [[pneumonia]], [[cor pulmonale]] or other complications.
===Pulmonary neoplasms===
The stage of the [[tumor]](s) has a major impact on [[neoplasm]] prognosis. Staging is the process of determining tumor size, growth rate, potential [[metastasis]], lymph node involvement, treatment options and prognosis. Two-year prognosis for limited small cell pulmonary neoplasms is twenty percent and for extensive disease five percent. The average life expectancy for someone with recurrent small cell pulmonary neoplasms is two to three months.[http://www.lungdiseasefocus.com/lung-cancer/cancer-prognosis.php]
The 5-year overall survival rate for pulmonary neoplasms is 14%.<ref>John D. Minna, "Neoplasms of the Lung," in ''Harrison's Principles of Internal Medicine'', 16th ed. (2005), p. 506</ref>
===Coronary heart disease===
{{main|Coronary heart disease}}
Chronic airway obstruction may be an independent risk factor for [[coronary heart disease]].<ref name="pmid3339378">{{cite journal |author=Ebi-Kryston KL |title=Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study |journal=J Clin Epidemiol |volume=41 |issue=3 |pages=251–60 |year=1988 |pmid=3339378 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0895-4356(88)90129-1 |issn=}}</ref>
Chronic airway obstruction may be an independent risk factor for [[coronary heart disease]].<ref name="pmid3339378">{{cite journal |author=Ebi-Kryston KL |title=Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study |journal=J Clin Epidemiol |volume=41 |issue=3 |pages=251–60 |year=1988 |pmid=3339378 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0895-4356(88)90129-1 |issn=}}</ref>


==Screening==
==Screening==
Chronic obstructive pulmonary disease should ''not'' be screened for according to [[clinical practice guideline]]s by the American College of Physicians<ref name="pmidpending">Qaseem A et al, “Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians,” November 6, 2007, http://www.annals.org/cgi/content/full/147/9/633 (accessed November 2, 2007).</ref>  and the Agency for Healthcare Research and Quality<ref>Agency for Healthcare Research and Quality (2005). “Use of Spirometry for Case Finding, Diagnosis, and Management of Chronic Obstructive Pulmonary Disease (COPD),” August 2005, http://www.ahrq.gov/clinic/tp/spirotp.htm (accessed November 2, 2007).</ref> This is due to the current lack of treatment for asymptomatic COPD and the inability of spirometric results to motivate smoking cessation.
Chronic obstructive pulmonary disease should ''not'' be screened for according to [[clinical practice guideline]]s by the American College of Physicians<ref name="pmidpending">Qaseem A et al, “Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians,” November 6, 2007, http://www.annals.org/cgi/content/full/147/9/633 (accessed November 2, 2007).</ref>  and the Agency for Healthcare Research and Quality<ref>Agency for Healthcare Research and Quality (2005). “Use of Spirometry for Case Finding, Diagnosis, and Management of Chronic Obstructive Pulmonary Disease (COPD),” August 2005, http://www.ahrq.gov/clinic/tp/spirotp.htm (accessed November 2, 2007).</ref> This is due to the current lack of treatment for asymptomatic COPD and the inability of spirometric results to motivate [[smoking cessation]].
 
"Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear" according to a [[randomized controlled trial]]. <ref name="pmid18326503">{{cite journal| author=Parkes G, Greenhalgh T, Griffin M, Dent R| title=Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. | journal=BMJ | year= 2008 | volume= 336 | issue= 7644 | pages= 598-600 | pmid=18326503 | doi=10.1136/bmj.39503.582396.25 | pmc=PMC2267989 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18326503  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18786330 Review in: J Fam Pract. 2008 Sep;57(9):584-6]  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18624373 Review in: ACP J Club. 2008 Jul;149(1):5]  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18667663 Review in: Evid Based Med. 2008 Aug;13(4):104]  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18583488 Review in: Evid Based Nurs. 2008 Jul;11(3):76] </ref>


== Epidemiology ==
== Epidemiology ==
Line 180: Line 288:


== References ==
== References ==
<references/>
<small>
<references>
 
</references>
</small>  
 
 
[[Category:Suggestion Bot Tag]]

Latest revision as of 09:53, 25 September 2024

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Chronic_obstructive_pulmonary_disease&printable=yes
This editable Main Article is under development and subject to a disclaimer.

Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive airway disease (COAD), is an obstructive lung disease that is characterized by the pathological limitation of airflow in the airway that is not fully reversible. This contrasts to asthma, an obstructive lung disease in which the obstruction is reversible.

COPD is the umbrella term for chronic bronchitis, emphysema and a range of other lung disorders. It is most often due to tobacco smoking,[1] but can be due to other airborne irritants such as coal dust, asbestos or solvents, as well as congenital conditions such as alpha-1-antitrypsin deficiency.

Signs and symptoms

The main symptoms of COPD include dyspnea (shortness of breath) lasting for months or perhaps years, possibly accompanied by wheezing, and a persistent cough with sputum production.[2] It is possible the sputum may contain blood (hemoptysis), usually due to damage of the blood vessels of the airways. Severe COPD could lead to cyanosis (bluish decolorization usually in the lips and fingers) caused by a lack of oxygen in the blood. In extreme cases it could lead to cor pulmonale due to the extra work required by the heart to get blood to flow through the lungs.[3]

COPD is particularly characterised by the spirometric measurement of a ratio of forced expiratory volume over 1 second (FEV1) to forced vital capacity (FVC) being < 0.7 and the FEV1 < 70% of the predicted value [4] as measured by a plethysmograph. Other signs include a rapid breathing rate (tachypnea) and a wheezing sound heard through a stethoscope. Pulmonary emphysema is NOT the same as subcutaneous emphysema, which is a collection of air under the skin that may be detected by the crepitus sounds produced on palpation.[5]

Causes

Cigarette smoking

A primary risk factor of COPD is chronic tobacco smoking. In the United States of America, around 90% of cases of COPD are due to smoking.[6] Not all smokers will develop COPD, but continuous smokers have at least a 25% risk.[7]

Occupational pollutants

Some occupational pollutants, such as cadmium and silica, have shown to be a contributing risk factor for COPD. The people at highest risk for these pollutants include coal workers, construction workers, metal workers and cotton workers, amongst others. However, in most cases these pollutants are combined with cigarette smoking further increasing the chance of developing COPD.[6] These occupations are commonly associated with other respiratory diseases, particularly pneumoconiosis (black lung disease). Asbestosis can appear even with minimal exposure.

Air pollution

Urban air pollution may be a contributing factor for COPD as it is thought to impair the development of the lung function. In developing countries indoor air pollution, usually due to biomass fuel, has been linked to COPD, especially in women.[1]

Genetics

Very rarely, there may be a deficiency in an enzyme known as alpha 1-antitrypsin which causes a form of COPD.[8]

Other risk factors

Increasing age, male gender, allergy, repeated airway infection and general impaired lung function are also related to the development of COPD.

Pathophysiology

Chronic bronchitis

Chronic bronchitis is defined in clinical terms as a cough with sputum production on most days for 3 months of a year, for 2 consecutive years.[9]

Chronic bronchitis is hallmarked by hyperplasia (increased number) and hypertrophy (increased size) of the goblet cells (mucous gland) of the airway, resulting in an increase in secretion of mucus which contributes to the airway obstruction. Microscopically there is infiltration of the airway walls with inflammatory cells, particularly neutrophils. Inflammation is followed by scarring and remodeling that thickens the walls resulting in narrowing of the small airway. Further progression leads to metaplasia (abnormal change in the tissue) and fibrosis (further thickening and scarring) of the lower airway. The consequence of these changes is a limitation of airflow.[10].

Emphysema

For more information, see: Emphysema.

Emphysema is defined histologically as the enlargement of the air spaces distal to the terminal bronchioles, with destruction of their walls.[9]

The enlarged air sacs (alveoli) of the lungs reduces the surface area available for the movement of gases during respiration. This ultimately leads to dyspnea in severe cases. The exact mechanism for the development of emphysema is not understood, although it is known to be linked with smoking and age.

Diagnosis

Clinical practice guidelines by a collaboration of American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society address diagnosis.[11]

The diagnosis of COPD is suggested by symptoms; it is a clinical diagnosis and no single test is definitive. A history is taken of smoking and occupation, and a physical examination is done. Measurement of lung function with a spirograph can reveal the loss of lung function.

The severity of COPD can be classified as follows using post-bronchodilator spirometry (see above)[12]:

Severity Post-bronchodilator FEV1 /FVC FEV1 % predicted
At risk >0.7 ≥80
Mild COPD ≤0.7 ≥80
Moderate COPD ≤0.7 50-80
Severe COPD ≤0.7 30-50
Very Severe COPD ≤0.7 <30 or 30-50 with Chronic Respiratory Failure symptoms

Physical examination

A systematic review by the Rational Clinical Examination concluded that no single medical sign or symptom can adequately exclude the diagnosis of COPD.[13] One study found that the presence of either "a history of smoking more than 30 pack-years, diminished breath sounds, or peak flow less than 350 L/min" has a sensitivity of 98 percent.[14]

Differential diagnosis

25% of patients with "unexplained exacerbation of chronic obstructive pulmonary disease" may have pulmonary embolism.[15]

Management

Although COPD is not curable, it can be controlled in a variety of ways. Clinical practice guidelines by Global Initiative for Chronic Obstructive Lung Disease (GOLD)[12], a collaboration including the American National Heart, Lung, and Blood Institute and the World Health Organization, as well as guidelines by the American College of Physicians published in 2011[16] and 2007[17][18] are available.

Smoking cessation

For more information, see: Smoking cessation.

Smoking cessation is one of the most important factors in slowing down the progression of COPD. Even at a late stage of the disease it can reduce the rate of deterioration and prolong the time taken for disability and death.[10]

Occupational change

Workers may be able to transfer to a significantly less contaminated area of the company depending on circumstances. Often however, workers may need complete occupational change.

Pharmacotherapy

Bronchodilators

There are several types of bronchodilators used clinically with varying efficacy: β2 agonists, M3 antimuscarinics, leukotriene antagonists, cromones and xanthines.[19] These drugs relax the smooth muscles of the airway allowing for improved airflow. Patients may feel less breathless after taking bronchodilators.

Older studies showed:

  • The β2 agonists and M3 antimuscarinics probably have similar efficacy[20]
  • All cause mortality may be worse for antimuscarinic according to a nested case-control study.[21]

More recent studies conclude differently and are in the table.

Major meta-analyses and randomized controlled trials of
bronchodilators for reducing all-cause mortality from COPD.[22][23][24][25]
Study/design Patients Intervention Outcome Results Comments
Treatment group Control group
Uplift study.[22]
Randomized controlled trial, 2008		 5993 patients Tiotropium All-cause mortality at 4 years 14.9% † 16.5% The Uplift study was too recent to be in the Singh meta-analysis.
"tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV1"
Singh et al.[23]
Meta-analysis, 2008		 14,783 in 17 trials Inhaled anticholinergics All-cause mortality 2% 1.6% "Inhaled anticholinergics are associated with a significantly increased risk of cardiovascular death, MI, or stroke among patients with COPD"
Rodrigo et al.[24]
Meta-analysis, 2008		 20,527 in 27 trials Long-Acting β-Agonists All-cause mortality 4.9% 6.5% "did not confirm previous data about an increased risk for respiratory deaths"
TORCH Study.[25]
Factorial randomized controlled trial, 2007		 6112 patients Long-Acting β-Agonists combined with inhaled corticosteroids All-cause mortality at 3 years 12.6% 15.2% This is the major trial in the Rodrigo meta-analysis
Long-Acting β-Agonists 13.5% 15.2%
Inhaled corticosteroids 16.0% 15.2%
Notes:
† Statistically significant difference.
β2 agonists
For more information, see: Adrenergic beta-agonist.

There is a tendency for long acting β2 agonists to reduce death, especially if they are combined with an inhaled corticosteroid.[26][24][25] β2 agonists may slow progression of airway obstruction[27].

An increased risk is associated with long acting β2 agonists among patients with asthma due to decreased sensitivity to inflammation so generally the use of a concomitant corticosteroid is indicated [28][29].

There are several highly specific β2 agonists available. Salbutamol (Ventolin) is the most widely used short acting β2 agonist to provide rapid relief and should be prescribed as a front line therapy for all classes of patients. Other β2 agonists are Bambuterol, Clenbuterol, Fenoterol, and Formoterol. Longer acting β2 agonists such as Salmeterol act too slowly to be used as relief for dypsnea so these drugs should be used as a secondary therapy.

M3 muscarinic cholinergic antagonists

Antagonists of the acetylcholine receptor include inhaled antimuscarinics. Antimuscarinics specific for M3 muscarinic recetpro the have the advantage of avoiding endocrine and exocrine M1 receptors. The quaternary M3 muscarinic antagonist Ipratropium can be prescribed alone or is offered combined with salbutamol (Combivent) and with fenoterol (Duovent). Tiotropium provides improved specificity for M3 muscarinic receptors and has been beneficial in trials.[30]

Anticholinergics may increase adverse effects.[21][23]

Cromones

Cromones are mast cell stabilizers that are thought to act on a chloride channel found on mast cells that help reduce the production of histamine and other inflammatory factors. Chromones are also thought to act on IgE-regulated calcium channels on mast cells. Cromoglicate and Nedocromil, which has a longer half-life, are two chromones available.[31]

Leukotriene antagonists

More recently leukotriene antagonists block the signaling molecules used by the immune system.[32] Montelukast, Pranlukast, Zafirlukast are some of the leukotrienes antagonists.[33]

Methylxanthines

Theophylline is the prototype of the methylxanthine[34] class of drug. Teas are natural sources of theophylline and caffeine while chocolate is a source of theobromine. Caffeine is approximately 16% metabolized into theophylline. Relatively little used, aminophylline as a derivative of theophylline, which can be given intraveously (IV).

Nebulized theophylline has uncertain value when used in the EMR for treatment of dyspnea (Difficulty in breathing).[35] Patients need continual monitoring as theophylline has a narrow therapeutic range. More aggressive EMR interventions include IV H1 antihistamines and IV glucocorticoids.

Corticosteroids

Although inhaled corticosteroids can reduced the forced expiratory volume when added to long acting adrenergic beta-agonists, they have uncertain benefit on clinical outcomes and may increase pneumonia[36] Budesonide may not increase the risk of pneumonia due to quicker clearing from the airways according to a separate meta-analysis.[37]

A factorial randomized controlled trial in the preceding meta-analyses compared salmeterol and fluticasone alone and in combination and found that the combination group tended to have the least mortality but that "the reduction in death from all causes among patients with COPD in the combination therapy group did not reach the predetermined level of statistical significance".[25]

Inhaled fluticasone may increase the risk of pneumonia.[25] Budesonide may not share this risk due to quicker clearing from the airways according to a meta-analysis.[37]

Corticosteroids may be combined with bronchodilators in a single inhaler. Some of the more common inhaled steroids in use are beclomethasone, mometasone, and fluticasone.

Oral or intravenous corticosteriods can help treat exacerbations of COPD.[38][39]

Antiboitics

Antibiotics for acute exacerbations of COPD accelerate improvement of symptoms.[40]

Antibiotics may prevent exacerbations.

Randomized controlled trials af antibiotics to prevent exacerbations of COPD.[41][42]
Trial Patients Intervention Comparison Outcome Results Comment
Intervention Control
COPD Clinical Research Network[41]
2011		 1577 patients
• 22% current smokers		 azithromycin orally 250 mg daily Placebo Mean number of exacerbations at 12 months 1.48 1.83 p = 0.01
Seemungal[42]
2008		 109 patients
• 48% current smokers		 erythromycin orally 250 mg twice daily Placebo Median number of exacerbations at 12 months 1 2 p = 0.006

Mucolytic agents

Mucolytic agents such as N-acetylcysteine (NAC) 400 mg daily up to 600 mg daily, especially patients not already using inhaled corticosteroids.[43]

TNF antagonists

Tumor necrosis factor-alpha antagonists (TNF-a) are the most recent class of medications designed to deal with refractory cases. TNF-a is a cachexin or cachectin. Its inhibitors, all monoclonal antibodies; they are immunosuppressive with attendant risks. These rather expensive drugs include infliximab, adalimumab and etanercept.[44]

Narcotics

For more information, see: Palliative care#Dyspnea.

Narcotics may relieve dyspnea according to a systematic review[45] and more recent narrative review[46].

Direct respiratory support

Appropriate oxygen therapy is different in acute and chronic COPD. "Oxygen is widely used but poorly studied in emergency medicine, with a limited evidence base for its use in specific conditions. There are safety concerns about the underuse of oxygen in patients with critical illness and its overuse in conditions such as .." COPD [47]

Supplemental Oxygen

Excessive oxygen can produce hypercapnia and hypercapnic acidosis in patients with acute exacerbations of COPD. In 2006, 30 patients with a history of previous hypercapnic acidosis with a Pao2 >10.0 kPa—indicating that oxygen may have worsened the hypercapnia— were given “O2 Alert” cards and a 24% Venturi mask. so that field and emergency room personnel do not cause iatrogenic hypercapnia. [48] A larger recent prospective trial in prehospital care randomized patients to receive high-flow oxygen or titrated oxygen. [49]

  • Titrating the oxygen, compared with high flow oxygen. lowered the risk of death for all patients by 58% for all patients (relative risk 0.42, 95% confidence interval 0.20 to 0.89; P=0.02). Overall mortality was 9% (21 deaths) in the high flow oxygen arm compared with 4% (7 deaths) in the titrated oxygen arm; mortality in the subgroup with confirmed COPD was 9% (11 deaths) in the high flow arm compared with 2% (2 deaths) in the titrated oxygen arm. and by 78% for the patients with confirmed chronic obstructive pulmonary disease (0.22, 0.05 to 0.91; P=0.04).
  • The risk of death was significantly lower in the titrated oxygen arm compared with the high flow oxygen arm for all patients (high flow oxygen n=226; titrated oxygen n=179) and for the subgroup of patients with confirmed COPD (high flow n=117; titrated n=97).
  • Patients with COPD who received titrated oxygen according to the protocol were significantly less likely to have respiratory acidosis (mean difference in pH 0.12 (SE 0.05); P=0.01; n=28) or hypercapnia (mean difference in arterial carbon dioxide pressure −33.6 (16.3) mm Hg; P=0.02; n=29) than were patients who received high flow oxygen.

Long-term administration of oxygen is usually reserved for individuals with COPD who have arterial hypoxemia (PaO2 less than 55 mm Hg), or a PaO2 between 55 and 60 mm Hg with evidence of pulmonary hypertension, cor pulmonale, or secondary erythrocytosis (hematocrit >55%). In these patients, continuous home oxygen therapy (for >15 h/d) sufficient to correct hypoxemia has been shown to improve survival.[50]

Noninvasive positive pressure ventilation

Noninvasive positive pressure ventilation, without raising the oxygen level, (NPPV) may help severe episodes.[51][52]

Vaccination

Patients with COPD should be routinely vaccinated against influenza, pneumococcus and other diseases to prevent illness and the possibility of death.[19]

Pulmonary rehabilitation

Pulmonary rehabilitation is a program of disease management, counseling and exercise coordinated to benefit the individual.[53] Pulmonary rehabilitation has been shown to relieve difficulties breathing and fatigue. It has also been shown to improve the sense of control a patient has over their disease as well as their emotions.[54]

Clinical practice guidelines address the use of pulmonary rehabilitation.[11]

Self management

Self management may help the patients who are successful in learning management.[55]

Diet

A recent French study conducted over 12 years with almost 43,000 men concluded that eating a Mediterranean diet "halves the risk of serious lung disease like emphysema and bronchitis". [3]

Prognosis

ADO index[56]
  0 points 1 points 2 points 3 points 4 points 5 points
FEV1 ≥65% 36% - 64% ≤ 35%
Dyspnea (MRC dyspnea scale) 0 - 1 2 3 4
Age (years) 40 - 49 50 - 59 60 - 69 70 - 79 80 - 89 ≥ 90
From Table 6[56]
ADO (age, dyspnea, obstruction) index and 3 year mortality[56]
  0 points 1 points 2 points 3 points 4 points 5 points 6 points 7 points 8 points 9 points 10 points
Patients with longstanding and severe COPD 7% 10% 14% 18% 24% 31% 39% 47% 56% 64% 72%
Patients after first hospitalization 3% 4% 5% 7% 10% 13% 17% 22% 28% 34% 42%
From Table 7[56]

Various clinical prediction rules are available to estimate prognosis.[56]

Chronic airway obstruction may be an independent risk factor for coronary heart disease.[57]

Screening

Chronic obstructive pulmonary disease should not be screened for according to clinical practice guidelines by the American College of Physicians[58] and the Agency for Healthcare Research and Quality[59] This is due to the current lack of treatment for asymptomatic COPD and the inability of spirometric results to motivate smoking cessation.

"Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear" according to a randomized controlled trial. [60]

Epidemiology

According to the World Health Organization (WHO), 80 million people suffer from moderate to severe COPD and 3 million died due to it in 2005. The WHO predicts that by 2030, it will be the 4th largest cause of mortality worldwide.[61]

Since COPD is not diagnosed until it becomes clinically apparent, prevalence and mortality data greatly underestimate the socioeconomic burden of COPD.[19] In the UK, COPD accounts for about 7% of all days of sickness related absence from work.[10]

Smoking rates in the industrialized world have continued to fall, causing rates of emphysema and pulmonary neoplasms to slowly decline.

References

  1. ↑ 1.0 1.1 Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. BMJ 2006;332:1142-1144. PMID 16690673
  2. ↑ U.S. National Heart Lung and Blood Institute - Signs and Symptoms
  3. ↑ MedicineNet.com - COPD signs & symptoms
  4. ↑ PatientPlus - Spirometry
  5. ↑ eMedicine - Barotrauma
  6. ↑ 6.0 6.1 MedicineNet.com - COPD causes
  7. ↑ Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006 Nov;61(11):935-9. PMID 17071833
  8. ↑ MedlinePlus Medical Encyclopedia
  9. ↑ 9.0 9.1 Longmore M, Wilkinson I, Rajagopalan S (2005). Oxford Handbook of Clinical Medicine, 6ed. Oxford University Press. pp 188-189. ISBN 0-19-852558-3.
  10. ↑ 10.0 10.1 10.2 Kumar P, Clark M (2005). Clinical Medicine, 6ed. Elsevier Saunders. pp 900-901. ISBN 0702027634.
  11. ↑ 11.0 11.1 Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T et al. (2011). "Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.". Ann Intern Med 155 (3): 179-91. DOI:10.1059/0003-4819-155-3-201108020-00008. PMID 21810710. Research Blogging.
  12. ↑ 12.0 12.1 Rabe KF, Hurd S, Anzueto A, et al (2007). "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary". Am. J. Respir. Crit. Care Med. 176 (6): 532–55. DOI:10.1164/rccm.200703-456SO. PMID 17507545. Research Blogging.
  13. ↑ Holleman DR, Simel DL (1995). "Does the clinical examination predict airflow limitation?". JAMA 273 (4): 313-9. PMID 7815660. [e]
  14. ↑ Badgett RG, Tanaka DJ, Hunt DK, et al (1994). "The clinical evaluation for diagnosing obstructive airways disease in high-risk patients". Chest 106 (5): 1427-31. PMID 7956395. [e]
  15. ↑ Tillie-Leblond I, Marquette CH, Perez T, et al (2006). "Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors". Ann. Intern. Med. 144 (6): 390–6. PMID 16549851. [e]
  16. ↑ Qaseem, Amir; Timothy J. Wilt, Steven E. Weinberger, Nicola A. Hanania, Gerard Criner, Thys van der Molen, Darcy D. Marciniuk, Tom Denberg, Holger Schünemann, Wisia Wedzicha, Roderick MacDonald, Paul Shekelle (2011). "Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society". Annals of Internal Medicine 155 (3): 179 -191. DOI:10.1059/0003-4819-155-3-201108020-00008. Retrieved on 2011-08-03. Research Blogging.
  17. ↑ Qaseem A, Snow V, Shekelle P, et al (2007). "Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians". Ann. Intern. Med. 147 (9): 633–8. PMID 17975186. [e]
  18. ↑ Wilt TJ, Niewoehner D, MacDonald R, Kane RL (2007). "Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline". Ann. Intern. Med. 147 (9): 639–53. PMID 17975187. [e]
  19. ↑ 19.0 19.1 19.2 American Thoracic Society / European Respiratory Society Task Force (2005). Standards for the Diagnosis and Management of Patients with COPD. Version 1.2. New York: American Thoracic Society. http://www.thoracic.org/go/copd
  20. ↑ Appleton S, Jones T, Poole P, et al. (2006). "Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease". Cochrane Database Syst Rev 3: CD006101. DOI:10.1002/14651858.CD006101. PMID 16856113. Research Blogging.
  21. ↑ 21.0 21.1 Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB (September 2008). "Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease". Ann. Intern. Med. 149 (6): 380–90. PMID 18794557. [e]
  22. ↑ 22.0 22.1 Tashkin DP, Celli B, Senn S, et al. (October 2008). "A 4-year trial of tiotropium in chronic obstructive pulmonary disease". N. Engl. J. Med. 359 (15): 1543–54. DOI:10.1056/NEJMoa0805800. PMID 18836213. Research Blogging.
  23. ↑ 23.0 23.1 23.2 Singh S, Loke YK, Furberg CD (September 2008). "Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis". JAMA 300 (12): 1439–50. DOI:10.1001/jama.300.12.1439. PMID 18812535. Research Blogging.
  24. ↑ 24.0 24.1 24.2 Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R (May 2008). "Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review". Chest 133 (5): 1079–87. DOI:10.1378/chest.07-1167. PMID 18460518. Research Blogging.
  25. ↑ 25.0 25.1 25.2 25.3 25.4 Calverley PM, Anderson JA, Celli B, et al (February 2007). "Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease". N. Engl. J. Med. 356 (8): 775–89. DOI:10.1056/NEJMoa063070. PMID 17314337. Research Blogging.
  26. ↑ Nannini LJ, Cates CJ, Lasserson TJ, Poole P (2007). "Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease". Cochrane Database Syst Rev (4): CD006829. DOI:10.1002/14651858.CD006829. PMID 17943918. Research Blogging.
  27. ↑ Celli BR, Thomas NE, Anderson JA, et al (August 2008). "Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study". Am. J. Respir. Crit. Care Med. 178 (4): 332–8. DOI:10.1164/rccm.200712-1869OC. PMID 18511702. Research Blogging.
  28. ↑ [1]
  29. ↑ [2]
  30. ↑ Niewoehner DE, Rice K, Cote C, et al. (September 2005). "Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial". Ann. Intern. Med. 143 (5): 317–26. PMID 16144890. [e]
  31. ↑ Howell JB, Altounyan RE (1967). "A double-blind trial of disodium cromoglycate in the treatment of allergic bronchial asthma". Lancet 2 (7515): 539–42. PMID 4166895. [e]
  32. ↑ Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF et al. (2011). "Leukotriene antagonists as first-line or add-on asthma-controller therapy.". N Engl J Med 364 (18): 1695-707. DOI:10.1056/NEJMoa1010846. PMID 21542741. Research Blogging.
  33. ↑ BROCKLEHURST WE (1960). "The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock". J. Physiol. (Lond.) 151: 416–35. PMID 13804592. [e]
  34. ↑ http://www.chemistry.org/portal/a/c/s/1/acsdisplay.html?DOC=HomeMolecule\archive\motw_xanthine_arch.html
  35. ↑ Duffy N, Walker P, Diamantea F, Calverley PM, Davies L (September 2005). "Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial". Thorax 60 (9): 713–7. DOI:10.1136/thx.2004.036046. PMID 15939732. PMC 1747521. Research Blogging.
  36. ↑ Rodrigo GJ, Castro-Rodriguez JA, Plaza V (2009). "Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review.". Chest 136 (4): 1029-38. DOI:10.1378/chest.09-0821. PMID 19633090. Research Blogging.
  37. ↑ 37.0 37.1 Sin DD, Tashkin D, Zhang X, Radner F, Sjöbring U, Thorén A et al. (2009). "Budesonide and the risk of pneumonia: a meta-analysis of individual patient data.". Lancet 374 (9691): 712-9. DOI:10.1016/S0140-6736(09)61250-2. PMID 19716963. Research Blogging.
  38. ↑ de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW (2007). "Oral or IV Prednisolone in the Treatment of COPD Exacerbations: A Randomized, Controlled, Double-blind Study". Chest 132 (6): 1741–7. DOI:10.1378/chest.07-0208. PMID 17646228. Research Blogging.
  39. ↑ Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB (2010). "Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease.". JAMA 303 (23): 2359-67. DOI:10.1001/jama.2010.796. PMID 20551406. Research Blogging.
  40. ↑ Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG (2010). "Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.". Am J Respir Crit Care Med 181 (2): 150-7. DOI:10.1164/rccm.200906-0837OC. PMID 19875685. Research Blogging.
  41. ↑ 41.0 41.1 Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ et al. (2011). "Azithromycin for prevention of exacerbations of COPD.". N Engl J Med 365 (8): 689-98. DOI:10.1056/NEJMoa1104623. PMID 21864166. Research Blogging.
  42. ↑ 42.0 42.1 Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA (2008). "Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.". Am J Respir Crit Care Med 178 (11): 1139-47. DOI:10.1164/rccm.200801-145OC. PMID 18723437. Research Blogging.
  43. ↑ Poole P, Black PN (2010). "Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.". Cochrane Database Syst Rev 2: CD001287. DOI:10.1002/14651858.CD001287.pub3. PMID 20166060. Research Blogging.
  44. ↑ http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/C/CellSignaling.html
  45. ↑ Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE (2002). "A systematic review of the use of opioids in the management of dyspnoea.". Thorax 57 (11): 939-44. PMID 12403875. PMC PMC1746225. Review in: ACP J Club. 2003 May-Jun;138(3):72 Review in: Evid Based Nurs. 2003 Jul;6(3):84
  46. ↑ Rocker G, Horton R, Currow D, Goodridge D, Young J, Booth S (2009). "Palliation of dyspnoea in advanced COPD: revisiting a role for opioids.". Thorax 64 (10): 910-5. DOI:10.1136/thx.2009.116699. PMID 19786716. Research Blogging.
  47. ↑ Hale KE, Gavin C, O'Driscoll BR (2008), "Audit of oxygen use in emergency ambulances and in a hospital emergency department", Emerg Med J 25: 773-776, DOI:10.1136/emj.2008.059287
  48. ↑ Gooptul B et al. (2006), "Oxygen alert cards and controlled oxygen: preventing emergency admissions at risk of hypercapnic acidosis receiving high inspired oxygen concentrations in ambulances and A&E departments", Emerg Med J 23: 636-638, DOI:10.1136/emj.2005
  49. ↑ Austin MA et al. (18 October 2010), "Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial", BMJ 2010: c5462, DOI:10.1136/bmj.c5462
  50. ↑ (1981) "Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party". Lancet 1 (8222): 681–6. DOI:10.1016/S0140-6736(81)91970-X. PMID 6110912. Research Blogging.
  51. ↑ Keenan SP, Sinuff T, Cook DJ, Hill NS (2003). "Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature.". Ann Intern Med 138 (11): 861-70. PMID 12779296.
  52. ↑ Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A et al. (1995). "Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.". N Engl J Med 333 (13): 817-22. PMID 7651472.
  53. ↑ U.S. National Heart Lung and Blood Institute - Treatment
  54. ↑ Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J (2011). "Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.". Cochrane Database Syst Rev (10): CD005305. DOI:10.1002/14651858.CD005305.pub3. PMID 21975749. Research Blogging.
  55. ↑ Bucknall CE, Miller G, Lloyd SM, Cleland J, McCluskey S, Cotton M et al. (2012). "Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial.". BMJ 344: e1060. DOI:10.1136/bmj.e1060. PMID 22395923. PMC PMC3295724. Research Blogging.
  56. ↑ 56.0 56.1 56.2 56.3 56.4 Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Antó JM, Agustí AG et al. (2009). "Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index.". Lancet 374 (9691): 704-11. DOI:10.1016/S0140-6736(09)61301-5. PMID 19716962. Research Blogging.
  57. ↑ Ebi-Kryston KL (1988). "Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study". J Clin Epidemiol 41 (3): 251–60. PMID 3339378. [e]
  58. ↑ Qaseem A et al, “Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians,” November 6, 2007, http://www.annals.org/cgi/content/full/147/9/633 (accessed November 2, 2007).
  59. ↑ Agency for Healthcare Research and Quality (2005). “Use of Spirometry for Case Finding, Diagnosis, and Management of Chronic Obstructive Pulmonary Disease (COPD),” August 2005, http://www.ahrq.gov/clinic/tp/spirotp.htm (accessed November 2, 2007).
  60. ↑ Parkes G, Greenhalgh T, Griffin M, Dent R (2008). "Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial.". BMJ 336 (7644): 598-600. DOI:10.1136/bmj.39503.582396.25. PMID 18326503. PMC PMC2267989. Research Blogging. Review in: J Fam Pract. 2008 Sep;57(9):584-6 Review in: ACP J Club. 2008 Jul;149(1):5 Review in: Evid Based Med. 2008 Aug;13(4):104 Review in: Evid Based Nurs. 2008 Jul;11(3):76
  61. ↑ WHO - COPD

Retrieved from "https://citizendium.org/wiki/index.php?title=Chronic_obstructive_pulmonary_disease&oldid=982614"